Loading...
XASXBTC
Market cap15mUSD
Jan 06, Last price  
0.08AUD
1D
0.00%
1Q
16.92%
Jan 2017
-33.91%
Name

BTC Health Ltd

Chart & Performance

D1W1MN
XASX:BTC chart
P/E
23.34
P/S
1,505.71
EPS
0.00
Div Yield, %
0.00%
Shrs. gr., 5y
18.59%
Rev. gr., 5y
-44.75%
Revenues
16k
+23.38%
020,00013,0002,000000037,71215,59611,35071,18428,496207,837317,763169,60419,19095,00413,26016,360
Net income
1m
P
-1,161,000-367,000-759,000-7,386,000-4,333,000-5,707,000-3,495,000-1,860,167-501,748-1,888,973-507,019-170,780-516,530-1,467,834-692,742-283,036-391,686-576,076-10,167,8621,055,287
CFO
-405k
L-6.65%
00000000-422,931-145,675-209,529-162,700-388,366-555,524-655,800-492,023-366,152-392,911-433,608-404,757
Dividend
Oct 19, 20120.01 AUD/sh
Earnings
Feb 21, 2025

Profile

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia. The fund invests in both listed and unlisted companies.
IPO date
Aug 29, 2000
Employees
1
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
16
23.38%
13
-86.04%
95
395.07%
Cost of revenue
550
Unusual Expense (Income)
NOPBT
16
13
(455)
NOPBT Margin
100.00%
100.00%
Operating Taxes
(492)
Tax Rate
NOPAT
16
13
37
Net income
1,055
-110.38%
(10,168)
1,665.02%
(576)
47.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
888
2,300
BB yield
-7.38%
-20.40%
Debt
Debt current
150
Long-term debt
Deferred revenue
105
105
105
Other long-term liabilities
(105)
(105)
(105)
Net debt
(4,937)
(2,937)
(12,840)
Cash flow
Cash from operating activities
(405)
(434)
(393)
CAPEX
(3)
Cash from investing activities
(198)
(2,206)
Cash from financing activities
888
2,400
FCF
16
8
3
Balance
Cash
2,022
1,737
2,170
Long term investments
2,915
1,200
10,820
Excess cash
4,936
2,936
12,986
Stockholders' equity
4,945
2,780
12,862
Invested Capital
9
(105)
150
ROIC
58.35%
2.73%
ROCE
0.33%
0.50%
EV
Common stock shares outstanding
316,459
281,846
281,846
Price
0.04
46.15%
0.03
-35.00%
0.04
-45.95%
Market cap
12,025
64.10%
7,328
-35.00%
11,274
-38.10%
EV
7,088
4,391
(1,566)
EBITDA
16
13
(455)
EV/EBITDA
433.28
331.15
3.45
Interest
Interest/NOPBT